Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Up to date there is no specific treatment method for severe IgAN,but trying ARB,omega-3,MRA,complement inhibitos,budesonide,endothelin inhibitors,complement inhibitors,SGLT2 inhibitors etc but eventually fall into ESRD. Cell based therapy especially SVF(stromal vascular fraction)/MSC(mesenchymal stem cell) is an emerging field in intractable immune mediated disorders,however reports in nephrology fieldis are very rare.We firstly reported 2 years promising results in severe IgAN by MP pulse and SVF therapy(2015,ASN). We further analyzed longterm follow up results
We selected severe IgAN as two groups,first group : clinically severe showing massive proteinuria more than 1,000mg/day. (GroupA), and second group : pathologically severe (stage IV/V by Lee's classification)(GroupB). We tried methylprednisolone (MP) pulse therapy followed by autologous SVF/MSC. Onew cycle of MP pulse is 20-30mg/kg/day for 3 consecutive days, we tried 3-17 cycles depends on the pathologic findings. Autologous SVF/MSC was obtained from abdominal fat.Mean cell count was 3x10(7)/injection(IV)
Three pts. were group A.Mean age 32 yrs.Mean initial eGFR before therapy was 85ml/min and 88 ml/min after therapy. Mean follow up period was 11.3 years. Eleven pts. were group B.Mean age 57 years.Mean initial eGFR before therapy were 26ml/min and 32ml/min after therapy. Mean follow up periods were 7.7 years.No pts.took dialysis even CKD stage 5 duiring 9 years follow up in one patient. Control patient who refused MP and SVF therapy but ARB,started hemodialysis in 2.5 yrs. No significant side-effects were noted. Follow up renal biopsy showed disppearance of EDD,reduced mesangial proliferation,improved epithelial foot process fusion and disappearance of IgA deposition by IF microscopy in group A & B.
MP pulse therapy and autologous SVF/MSC have showed promising results without signicant side-effects in severe IgAN. Although further longterm and large number studies are mandatory.
